Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra study in percutaneous coronary intervention: A randomized evaluation (ASPIRE) pilot trial

Circulation

Volumn 111, Issue 11, 2005, Pages 1390-1397

  Mehta, Shamir R ^a,k   Steg, Philippe Gabriel ^b   Granger, Christopher B ^c   Bassand, Jean Pierre ^d   Faxon, David P ^e   Weitz, Jeffrey I ^a   Afzal, Rizwan ^a   Rush, Bonnie ^a   Peters, Ron J G ^f   Natarajan, Madhu K ^a   Velianou, James L ^a   Goodhart, David M ^g   Labinaz, Marino ^h   Tanguay, Jean Francois ⁱ   Fox, Keith A A ^j   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b BICHAT HOSPITAL   (France)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^e UNIVERSITY OF CHICAGO   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g Foothills Medical Center   (Canada)

^h UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^k HAMILTON HEALTH SCIENCES   (Canada)

more..

Author keywords

Angioplasty; Anticoagulants; Complications; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MARKER; PROTHROMBIN; THROMBIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; FALSE ANEURYSM; FEASIBILITY STUDY; FEMALE; HEART INFARCTION; HEMATOMA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; THROMBOSIS; TIME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; EMERGENCIES; FACTOR XA; FEASIBILITY STUDIES; FEMALE; HEMORRHAGE; HEPARIN; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PILOT PROJECTS; POLYSACCHARIDES; SINGLE-BLIND METHOD; STENTS; TREATMENT OUTCOME;

EID: 20144373165     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000158485.70761.67     Document Type: Article

References (22)

1. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antiplatelet therapy in patients undergoing percutaneous coronary intervention. Chest. 2001;119:321S-336S.
2. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes K, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2001;37:2239i-2239lxvi.
3. Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001;119:95S-107S.
4. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001;58:S14-S17.
5. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619-625.
6. Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715-1720.
7. Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721-1726.
8. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
9. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
10. Vuillemenot A, Schiele F, Meneveau N, Claudel S, Donat F, Fontecave S, Cariou R, Samama MM, Bassand JP. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81:214-220.
11. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van de Werf F; PENTALYSE Investigators. A synthetic factor-Xa inhibitor ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J. 2001;22:1716-1724.
12. Simoons ML, Bobbink IW, Boland J. Gardien M, Klpotwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U, PENTUA Investigators. A dose-finding study of fondaparinux in patients with non ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol. 2004;43:2183-2190.
13. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977;10:399-410.
14. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S, Copland I, Fox KAA, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
15. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
16. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
17. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
18. Uretsky BF, Denys BG, Counhan PC, Ragosta M. Angioscopic evaluation of incomplelely obstructing coronary intraluminal filling defects: comparison to angiography. Cathet Cardiovasc Diagn. 1994; 33:323-329.
19. den Heijer P, Foley DP, Escamed J, Hillege HL, van Dijk RB, Serruys PW, Lie KI. Angioscopic versus angiographic detection of intimal dissection and intracoronary thrombus. J Am Coll Cardiol. 1994;24:649-654.
20. Mizuno K, Miyamoto A, Satomura K, Kurita A, Aria T, Sakurada M, Yanagida S, Nakamura H. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet. 1991;337:809-812.
21. Teirstein PS, Schatz RA, DeNardo SJ, Jensen EE, Johnson AD. Angioscopic versus angiographic detection of thrombus during coronary interventional procedures. Am J Cardiol. 1995;75:1083-1087.
22. White CJ, Ramee SR, Collins TJ, Escobar AE, Karsan A, Shaw D, Jain SP, Bass TA, Henser RR, Teirstein PS, Bonan R, Walter PD, Smalling RW. Coronary thrombi increase PTCA risk: angioscopy as a clinical tool. Circulation. 1996;93:253-258.